**1. Introduction**

In the United States, the incidence rate of colon cancer increased by 0.5% to 2.4% annually since the mid-1980s in adults aged 20 to 54 years. Moreover, the rectal cancer incidence rate also increased faster by 3.2% annually since the 1970s in relatively younger ages (20–29 years) [1]. The recent global trend of colorectal cancer has been reported to have confirmed about 1.14 million, which accounts for about 6% of all newly diagnosed cancer patients, and the annual mortality is approaching about 580 K [2]. Such facts make it possible to recognize the high incidence rate and mortality of colorectal cancer, and it gives a continuous challenge to conquer colorectal cancer for physicians and basic researchers. Up to now, a variety of treatments have been developed as strategies responding to metical unmet needs while succeeding with existing therapeutic options targeting colorectal cancer, and those options are still effective. Therefore, a broad understanding of recent therapies including the past things will be essential to lay the groundwork for the step-by-step process of making innovations in colorectal cancer treatment.
